Mirum Pharmaceuticals (MIRM) Gains from Sales and Divestitures (2019 - 2022)

Mirum Pharmaceuticals' Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $122464.0 for Q4 2022.

• In Q4 2022, Gains from Sales and Divestitures fell 8.33% year-over-year to $122464.0; the TTM figure through Dec 2022 stood at $122464.0 (down 8.33% YoY), while the FY2022 annual figure was $122464.0, down 8.33% from the prior year.
• Gains from Sales and Divestitures was $122464.0 for Q4 2022 at Mirum Pharmaceuticals, up from $100194.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $135350.0 in Q4 2019 to a low of $33396.0 in Q1 2021.
• Historically, Gains from Sales and Divestitures has averaged $76867.0 across 4 years, with a median of $67675.0 in 2019.
• The sharpest annual moves came in 2020 and 2021: Gains from Sales and Divestitures surged 200.0% in 2020, then sank 50.0% in 2021.
• A 4-year view of Gains from Sales and Divestitures shows it stood at $135350.0 in 2019, then retreated by 1.3% to $133593.0 in 2020, then changed by 0.0% to $133593.0 in 2021, then fell by 8.33% to $122464.0 in 2022.
• The last three Gains from Sales and Divestitures figures came in at $122464.0 (Q4 2022), $100194.0 (Q3 2022), and $66796.0 (Q2 2022), per Business Quant data.